PDF(Pubmed)
Abstract：
Nuclear receptor subfamily 1, group D, member 1 (NR1D1, also known as REV-ERBα) belongs to the nuclear receptor (NR) family, and is a heme-binding component of the circadian clock that consolidates circadian oscillators. In addition to repressing the transcription of multiple clock genes associated with circadian rhythms, NR1D1 has a wide range of downstream target genes that are intimately involved in many physiopathological processes, including autophagy, immunity, inflammation, metabolism and aging in multiple organs. This review focuses on the pivotal role of NR1D1 as a key transcription factor in the gene regulatory network, with particular emphasis on the milestones of the latest discoveries of NR1D1 ligands. NR1D1 is considered as a promising drug target for treating diverse diseases and may contribute to research on innovative biomarkers and therapeutic targets for organ injury-related diseases. Further research on NR1D1 ligands in prospective human trials may pave the way for their clinical application in many organ injury-related disorders.
摘要：
核受体亚家族1，D组，成员1（NR1D1，也称为REV-ERBα）属于核受体（NR）家族，并且是昼夜节律钟的血红素结合成分，可巩固昼夜节律振荡器。除了抑制与昼夜节律相关的多个时钟基因的转录，NR1D1具有广泛的下游靶基因，这些基因与许多病理生理过程密切相关。包括自噬,豁免权,炎症,多器官的新陈代谢和衰老。本文就NR1D1作为基因调控网络中的关键转录因子,特别强调NR1D1配体最新发现的里程碑。NR1D1被认为是治疗多种疾病的有前途的药物靶标，可能有助于研究器官损伤相关疾病的创新生物标志物和治疗靶标。在前瞻性人体试验中对NR1D1配体的进一步研究可能为其在许多器官损伤相关疾病中的临床应用铺平道路。
